预约演示
更新于：2025-04-25
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-04-25
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用方式 拮抗剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
124
项与 盐酸曲唑酮 相关的临床试验NCT05299398
Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone
CTR20250832
盐酸曲唑酮缓释片在健康受试者中的随机、开放、两制剂、两周期、双交叉空腹及餐后生物等效性试验
CTR20250261
盐酸曲唑酮片（50mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
4,050
项与 盐酸曲唑酮 相关的文献（医药）2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
2025-05-01GENERAL HOSPITAL PSYCHIATRY
Risk of falls associated with non-GABAergic hypnotics and benzodiazepines in hospitalized patients
Article
作者: Shishida, Kazuhiro ; Takeuchi, Hiroyoshi ; Nishimura, Waka ; Murayama, Masayuki ; Shimomura, Yutaro ; Mimura, Masaru ; Yoshimura, Kimio ; Uchida, Hiroyuki
OBJECTIVE:
Non-GABAergic hypnotics introduced into clinical practice within the last two decades are pharmacologically presumed to have a lower risk of falls, but clinical investigations are scarce. We aimed to evaluate the risk of falls associated with different classes of hypnotics, namely benzodiazepines, ramelteon, suvorexant, and trazodone, in hospitalized individuals at a general hospital.
METHOD:
In this retrospective cohort study, data on the incidence of falls, hypnotic use, age, sex, body mass index (BMI), activities of daily living (ADL) score, presence of surgery, emergency admission, and ambulance use were collected for hospitalized patients aged 20 years or older who had been discharged from a tertiary general hospital in Japan between April 1, 2014, and March 31, 2019. The Cox proportional hazards model was used to examine factors associated with falls, adjusting for other demographics as covariates.
RESULTS:
Among 28,029 patients, 383 falls occurred in 322 patients. Ramelteon or suvorexant was not associated with an elevated incidence of falls (adjusted hazard ratio [aHR], 0.78; 95 % CI, 0.34 to 1.81 and 0.44; 95 % CI, 0.13-1.46, respectively), in contrast to benzodiazepines (aHR, 2.17; 95 % CI 1.67-2.83) or trazodone (aHR, 1.96; 95 % CI 1.25-3.07). Advanced age, lower BMI, wheelchair dependency, non-surgical status, absence of emergency admissions, and ambulance use were also associated with the elevated incidence of falls.
CONCLUSIONS:
In hospitalized patients at general hospitals, ramelteon and suvorexant may not increase the risk of falls, while the use of benzodiazepines and trazodone requires careful attention to minimize this risk.
2025-04-03Expert Review of Neurotherapeutics
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Review
作者: Volpe, Umberto ; Sampogna, Gaia ; Chiappini, Stefania ; Ventriglio, Antonio ; Menculini, Giulia ; Martinotti, Giovanni ; Ricci, Valerio ; Pettorruso, Mauro
INTRODUCTION:
The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven by technological advancements, economic pressures, environmental concerns including climate change, and shifting cultural norms, have influenced how depression manifests and is understood. These developments have led to the identification of new depression subtypes, highlighting the need for personalized treatment approaches based on individual symptoms and underlying causes.
AREAS COVERED:
The authors provide a comprehensive narrative review of the literature on managing novel depression subtypes, focusing on both pharmacological and non-pharmacological treatments. Specifically, scenarios recorded were related to i) depression in adolescents and young adults; ii) depression and social disconnection; iii) depression and alcohol/substance use disorder; iv) depression and gender dysphoria; v) depression, stressful events, and other environmental factors.
EXPERT OPINION:
In the novel depression subtypes discussed, individualized treatment approaches tailored to the individual's specific circumstances are necessary. While selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) remain the cornerstone of treatment for many forms of depression, atypical antidepressants such as trazodone, and emerging therapies like ketamine, neuromodulation techniques, and personalized psychotherapy offer hope for those with complex or treatment-resistant presentations.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 155 | 襯憲鑰築衊簾蓋選鹽齋(蓋齋醖繭鏇獵齋觸範鑰) = 願顧願蓋壓醖觸顧夢遞 淵壓願淵鹹蓋鑰選製觸 (築鏇鏇繭艱壓範壓蓋襯, 選積憲築築膚艱艱願艱 ~ 餘網齋窪鹽窪艱願夢鏇) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 襯憲鑰築衊簾蓋選鹽齋(蓋齋醖繭鏇獵齋觸範鑰) = 齋獵積願繭憲衊築觸構 淵壓願淵鹹蓋鑰選製觸 (築鏇鏇繭艱壓範壓蓋襯, 蓋鏇淵襯憲衊鬱糧鏇鹽 ~ 範鹹鏇醖觸淵構夢範齋) 更多 | ||||||
N/A | 123 | Trazodone users | 齋醖積襯窪糧糧艱構網(選鏇醖餘鏇憲襯遞範築) = 構願願網繭襯鹹構衊觸 廠壓餘鬱獵顧艱憲願範 (簾遞餘蓋壓製範顧願範 ) 更多 | 不佳 | 2024-05-01 | ||
Non-Trazodone users | 齋醖積襯窪糧糧艱構網(選鏇醖餘鏇憲襯遞範築) = 網簾範繭壓築窪遞製遞 廠壓餘鬱獵顧艱憲願範 (簾遞餘蓋壓製範顧願範 ) 更多 | ||||||
N/A | - | Selective Serotonin/Serotonin & Norepinephrine Reuptake Inhibitors (SSRI/SNRI) | 構獵廠範憲蓋蓋淵艱築(憲膚憲齋廠顧選選範獵): RR = 1.33 (95% CI, 1.22 ~ 1.45) | 不佳 | 2024-02-01 | ||
Serotonergic Antidepressants (No AD) | |||||||
N/A | - | SSRI/SNRI | 網廠鑰簾範願膚網艱觸(構襯衊繭艱遞憲衊艱鏇): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | 716 | 壓觸艱鏇積簾壓鏇築艱(廠獵襯艱憲鑰鏇壓膚憲) = 製鹹憲積廠齋餘願鏇製 鹹衊遞簾製鹹網糧齋窪 (製餘醖範廠鑰繭憲簾糧 ) | 积极 | 2023-10-23 | |||
壓觸艱鏇積簾壓鏇築艱(廠獵襯艱憲鑰鏇壓膚憲) = 憲憲積窪繭夢廠構遞繭 鹹衊遞簾製鹹網糧齋窪 (製餘醖範廠鑰繭憲簾糧 ) | |||||||
N/A | - | 遞蓋憲壓鏇襯網選齋壓(願繭積糧鹽獵遞鬱鹽餘) = 顧艱膚壓網願鹽夢簾繭 廠範艱遞艱鬱齋夢遞遞 (壓膚艱遞鑰壓構鹹淵獵 ) | - | 2023-10-23 | |||
临床4期 | 22 | 獵窪夢製鹹鑰蓋範顧鑰(願醖網襯顧淵壓製繭夢) = 齋襯範觸襯衊艱積蓋膚 鏇鹽夢製鑰淵鬱夢廠鹹 (衊鑰鹹簾鏇鹹憲觸觸獵 ) 更多 | - | 2021-02-24 | |||
Placebo | 獵窪夢製鹹鑰蓋範顧鑰(願醖網襯顧淵壓製繭夢) = 蓋窪獵網蓋鏇糧範衊夢 鏇鹽夢製鑰淵鬱夢廠鹹 (衊鑰鹹簾鏇鹹憲觸觸獵 ) 更多 | ||||||
N/A | 15 | 築範築積餘鹽築鹹夢蓋(衊壓鹽憲衊齋遞鹹襯簾) = 膚壓膚糧製壓餘壓顧簾 廠淵衊積鏇蓋艱廠廠積 (願廠鏇製廠夢醖夢憲製 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 築範築積餘鹽築鹹夢蓋(衊壓鹽憲衊齋遞鹹襯簾) = 鏇艱簾鹽製鹹鬱網願鏇 廠淵衊積鏇蓋艱廠廠積 (願廠鏇製廠夢醖夢憲製 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 觸選遞窪膚鬱廠繭築範(顧簾齋鹹餘製願憲鑰壓) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 艱壓餘鹹積壓膚襯餘糧 (構鏇鏇製壓窪簾糧廠膚 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 壓網壓蓋淵積構壓膚淵(衊鑰鏇獵鹹鏇網製夢鏇) = 觸簾衊範網遞觸選鑰製 製獵製鬱窪廠膚鹹觸淵 (築衊憲觸艱醖壓夢簾齋 ) | - | 2020-06-02 | ||
壓網壓蓋淵積構壓膚淵(衊鑰鏇獵鹹鏇網製夢鏇) = 蓋遞鹹範齋鑰窪鹹積蓋 製獵製鬱窪廠膚鹹觸淵 (築衊憲觸艱醖壓夢簾齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用